We are live on ! Find out more
SCM

Sarissa Capital Management Portfolio holdings

AUM $158M
1-Year Est. Return 103.7%
This Fund
S&P 500
This Quarter Est. Return
+13.1%
1 Year Est. Return
+103.7%
3 Year Est. Return
+58.62%
5 Year Est. Return
+92.85%
10 Year Est. Return
+667.68%
AUM
$283M
AUM Growth
+$23.6M
Cap. Flow
-$2.07M
Cap. Flow %
-0.73%
Top 10 Hldgs %
97.4%
Holding
18
New
3
Increased
2
Reduced
2
Closed
2

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$30.9M
2
KIN
Kindred Biosciences, Inc.
KIN
+$2.54M
3
SEEL
Seelos Therapeutics, Inc. Common Stock
SEEL
+$1.52M
4
ANIP icon
ANI Pharmaceuticals
ANIP
+$1.37M
5
CARM
Carisma Therapeutics
CARM
+$462K

Top Sells

Rank Stock Value
1
BRLI
BIO-REFERENCE LABS INC-NEW-
BRLI
+$25.8M
2
A icon
Agilent Technologies
A
+$7.38M
3
ENTA icon
Enanta Pharmaceuticals
ENTA
+$4.16M
4
TRAW icon
Traws Pharma
TRAW
+$1.5M

Sector Composition

Rank Sector Weight
1 Healthcare 93.74%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARIA
1
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$88.3M 31.25%
12,850,000
– –
DGX icon
2
Quest Diagnostics
DGX
$25.7B
$52M 18.4%
775,000
– –
AMGN icon
3
Amgen
AMGN
$208B
$50.7M 17.93%
318,000
+198,000
+165% +$30.9M
MRK icon
4
Merck
MRK
$322B
$22.7M 8.04%
419,200
– –
A icon
5
Agilent Technologies
A
$39.1B
$18.8M 6.67%
460,000
-183,080
-28% -$7.38M
BRLI
6
DELISTED
BIO-REFERENCE LABS INC-NEW-
BRLI
$12.5M 4.44%
390,270
-890,714
-70% -$25.8M
RPRX
7
DELISTED
Repros Therapeutics Inc.
RPRX
$11.3M 4%
1,132,367
– –
VVUS
8
DELISTED
Vivus Inc
VVUS
$7.41M 2.62%
257,394
– –
ITCI
9
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$6.35M 2.25%
360,000
– –
KIN
10
DELISTED
Kindred Biosciences, Inc.
KIN
$5.13M 1.82%
689,091
+299,091
+77% +$2.54M
AVEO
11
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$2.16M 0.76%
257,076
– –
ANIP icon
12
ANI Pharmaceuticals
ANIP
$1.8B
$1.75M 0.62%
+31,000
New +$1.37M
GYRE icon
13
Gyre Therapeutics
GYRE
$641M
$1.66M 0.59%
800
– –
SEEL
14
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
$1.03M 0.36%
+1
New +$1.52M
CARM
15
DELISTED
Carisma Therapeutics
CARM
$489K 0.17%
+2,060
New +$462K
BGMS
16
Bio Green Med Solution Inc
BGMS
$4.91M
– –
0
– –
ENTA icon
17
Enanta Pharmaceuticals
ENTA
$366M
– –
-105,000
Closed -$4.16M
TRAW icon
18
Traws Pharma
TRAW
$6.85M
– –
-6
Closed -$1.5M

Similar funds

4A
4D Advisors Redondo Beach, California $158M AUM 92.73% 1-Year Est. Return
DAM
Deepwater Asset Management Minneapolis, Minnesota $158M AUM 23.9% 1-Year Est. Return
PCP
Pantera Capital Partners San Francisco, California $158M AUM 600.89% 1-Year Est. Return
CF
CDC Financial Chicago, Illinois $157M AUM
HEM
Henson-Edgewater Management Avon, Ohio $157M AUM
SF
Seros Financial Tempe, Arizona $157M AUM 16.95% 1-Year Est. Return
AC
AlpenGlobal Capital Tahoe City, California $157M AUM
EP
Elkhorn Partners Omaha, Nebraska $157M AUM 11.91% 1-Year Est. Return

Sarissa Capital Management's Q4 2014 Portfolio in Review

As of Q4 2014, Sarissa Capital Management held 18 positions worth $283M, up 9.1% from $259M the previous quarter. Its ten largest holdings account for 97% of the portfolio.

Sarissa Capital Management's Q4 2014 filing shows 3 new, 2 increased, 2 reduced and 2 closed positions. Its largest new stake was Seelos Therapeutics, Inc. Common Stock: 1 share worth $1.03M. The largest sale was BIO-REFERENCE LABS INC-NEW-, an estimated $25.8M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 85% a quarter earlier.

  • Sarissa Capital Management's largest Q4 2014 buy was Seelos Therapeutics, Inc. Common Stock: 1 share worth $1.03M.
  • Sarissa Capital Management added most to Amgen in Q4 2014, an estimated $30.9M increase.
  • Sarissa Capital Management's biggest Q4 2014 reduction was BIO-REFERENCE LABS INC-NEW-, cutting an estimated $25.8M.
  • Sarissa Capital Management fully exited Enanta Pharmaceuticals in Q4 2014, selling an estimated $4.16M.
  • Sarissa Capital Management's ten largest holdings make up 97% of its $283M portfolio in Q4 2014.
  • Sarissa Capital Management opened 3 new positions and closed 2 in Q4 2014.
  • Sarissa Capital Management's portfolio value rose 9.1% quarter-over-quarter to $283M.

Based on Sarissa Capital Management's 13F filing for Q4 2014, filed 17 Feb 2015.